ReviewChemical reviews2025
From Concepts to Inhibitors: A Blueprint for Targeting Protein-Protein Interactions.
Review in Chemical reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Dibenzo[International journal of molecular sciences · 2026Article
- De Novo-Designed Bifunctional Proteins for Targeted Protein Degradation.Journal of the American Chemical Society · 2026Article
- TRIM28-Derived Peptide Exerts Anti-Tumor Roles by Stabilizing Tumor Suppressive BRD7 Protein in Multiple Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Photoredox-Catalyzed Lysine C(spJournal of the American Chemical Society · 2026Article
- Structural and evolutionary insights into DAF-12 interactions with transcriptional coactivators in parasitic nematodes.PLoS pathogens · 2026Article
- Advancing protein engineering via organic chemistry.Communications chemistry · 2026Review
- Linker Engineering in Stapled Peptides for Enhanced Membrane Permeability: Screening and Optimization Strategies.International journal of molecular sciences · 2026Review
- Integrating Functional Response and Target Binding for Mechanism-Centered Drug Screening by High-Mass MALDI-MS.ACS central science · 2026Article
- Computational Study of Terahertz-Induced Phase Transitions at Molecular Interfaces.Research (Washington, D.C.) · 2026Article
- Protein-Protein Interactions as Promising Molecular Targets for Novel Antimicrobials Aimed at Gram-Negative Bacteria.International journal of molecular sciences · 2025Review
- Pharmacophore-driven antibody discovery on the yeast surface.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Protein-protein interactions are no longer considered undruggable because of the conceptual and technical advances that allow inhibitors to be generated using rational design principles and high-throughput screening methods. Here we review the concepts and approaches that have underpinned the progress in this field. We begin by assessing what makes a protein surface more tractable than others with a focus on the recent success in targeting Ras, which has long served as a poster child of a therapeutically important yet undruggable target. We discuss computational approaches to dissect protein surfaces to design macrocycles and miniprotein ligands. Traditional drug discovery has benefitted from leveraging natural products but this benefit has not extended to the design of ligands for protein surfaces because few natural products have been characterized as inhibitors of protein complexes. However, nature does provide a template in the form of binding epitopes of partner proteins. We review design of protein structure mimics that enable rational design of inhibitors through multiple weak contacts. Lastly, we focus on contemporary screening methods that are being merged with constrained peptides to offer unprecedented side chain diversity on conformationally defined scaffolds. We will focus on the concepts underlying advancements in the field rather than the application of these concepts and technologies that have led to inhibitors of specific interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.